These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16702818)

  • 41. High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia.
    Nemet D; Labar B; Bogdanić V; Hauptman E; Jaksić B; Minigo H; Sertić D; Mrsić M; Pavletić Z; Kovacević J
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():42-4. PubMed ID: 2697399
    [No Abstract]   [Full Text] [Related]  

  • 42. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
    Al Bahar S; Pandita R; Bavishi K; Savani B
    Neoplasma; 1999; 46(1):61-5. PubMed ID: 10355536
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
    Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Martínez-Cuadrón D; Rojas L; Rodríguez-Veiga R; Boluda B; Sendra L; Cervera J; Poveda JL; Sanz MÁ; Aliño SF
    Leuk Lymphoma; 2017 Dec; 58(12):2880-2894. PubMed ID: 28573946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Myelodysplastic syndrome and myelogenous leukemia. Treatment with low-dose cytarabine].
    Waage A; Hammerstrøm J; Lødemel B; Hoff JE; Langtind J
    Tidsskr Nor Laegeforen; 1986 Feb; 106(6):496-7. PubMed ID: 3457484
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside.
    Kufe DW; Spriggs DR; Griffin JD
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):149-58. PubMed ID: 3473675
    [No Abstract]   [Full Text] [Related]  

  • 47. Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia.
    Estey E; Keating MJ; Plunkett W; McCredie KB; Freireich EJ
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):58-63. PubMed ID: 3473684
    [No Abstract]   [Full Text] [Related]  

  • 48. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside.
    Griffin JD; Spriggs D; Wisch JS; Kufe DW
    J Clin Oncol; 1985 Jul; 3(7):982-91. PubMed ID: 4020409
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High Dose Cytosine Arabinoside in the consolidation of adult acute myeloid leukemia.
    Rahman MH; Khan MA; Islam MS; Afrose S; Ara T
    Mymensingh Med J; 2012 Apr; 21(2):213-9. PubMed ID: 22561761
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
    Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
    Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Refractory acute myelogenous leukemia successfully treated with a continuous infusion chemotherapy of low dose aclarubicin and cytosine arabinoside: a case report].
    Kawada H; Komatsuda M; Masumoto A; Fukuda R; Watanabe S; Yonekura S; Ichikawa Y; Nagao T; Arimori S
    Rinsho Ketsueki; 1993 May; 34(5):667-9. PubMed ID: 8315839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia.
    Palle J; Frost BM; Petersson C; Hasle H; Hellebostad M; Kanerva J; Schmiegelow K; Lönnerholm G;
    Anticancer Drugs; 2009 Jan; 20(1):7-14. PubMed ID: 19342996
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia.
    Azevedo MC; Velloso ED; Buccheri V; Chamone DA; Dorlhiac-Llacer PE
    Braz J Med Biol Res; 2015 Feb; 48(2):178-85. PubMed ID: 25517921
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Slower degradation rate of cytarabine in blood samples from acute myeloid leukemia by comparison with control samples.
    Abbara C; Drevin G; Férec S; Ghamrawi S; Souchet S; Robin JB; Schmidt A; Hunault-Berger M; Guardiola P; Briet M
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):687-691. PubMed ID: 32990804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman.
    Friedman JH; Shetty N
    Mov Disord; 2001 May; 16(3):575-7. PubMed ID: 11391764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cashen AF; Shah AK; Todt L; Fisher N; DiPersio J
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):759-66. PubMed ID: 17564707
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
    Malpas J; Mathé G; Hayat M
    Bull Cancer; 1974; 61(3):411-8. PubMed ID: 4533741
    [No Abstract]   [Full Text] [Related]  

  • 60. Cytarabine dose for acute myeloid leukemia.
    Mathisen MS
    N Engl J Med; 2011 Jun; 364(22):2167; author reply 2168-9. PubMed ID: 21631341
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.